Tempest Therapeutics Inc


Prices are adjusted according to historical splits.

Tempest Therapeutics Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$7.20 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Tempest Therapeutics Inc had its IPO on 2012-11-12 under the ticker symbol TPST.

The company operates in the Healthcare sector and Biotechnology industry. Tempest Therapeutics Inc has a staff strength of 19 employees.

Stock update

Shares of Tempest Therapeutics Inc opened at $0.44 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.44 - $0.58, and closed at $0.57.

This is a +30.14% increase from the previous day's closing price.

A total volume of 504,466 shares were traded at the close of the day’s session.

In the last one week, shares of Tempest Therapeutics Inc have increased by +5.56%.

Tempest Therapeutics Inc's Key Ratios

Tempest Therapeutics Inc has a market cap of $7.20 million, indicating a price to book ratio of 0.6148 and a price to sales ratio of 0.

In the last 12-months Tempest Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-32130000. The EBITDA ratio measures Tempest Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Tempest Therapeutics Inc’s operating margin was 0% while its return on assets stood at -40.11% with a return of equity of -166.57%.

In Q2, Tempest Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Tempest Therapeutics Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-2.16 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Tempest Therapeutics Inc’s profitability.

Tempest Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.2975. Its price to sales ratio in the trailing 12-months stood at 0.

Tempest Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$30.74 million
Total Liabilities
$8.64 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Tempest Therapeutics Inc ended 2023 with $30.74 million in total assets and $0 in total liabilities. Its intangible assets were valued at $30.74 million while shareholder equity stood at $5.01 million.

Tempest Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $8.64 million in other current liabilities, 13000.00 in common stock, $-150989000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $17.60 million and cash and short-term investments were $17.60 million. The company’s total short-term debt was $4,388,000 while long-term debt stood at $7.48 million.

Tempest Therapeutics Inc’s total current assets stands at $18.54 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $868000.00 and inventory worth $0.

In 2023, Tempest Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $117000.

Comparatively, Tempest Therapeutics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Tempest Therapeutics Inc stock is currently trading at $0.57 per share. It touched a 52-week high of $4.214 and a 52-week low of $4.214. Analysts tracking the stock have a 12-month average target price of $15.67.

Its 50-day moving average was $0.82 and 200-day moving average was $1.52 The short ratio stood at 0.1 indicating a short percent outstanding of 0%.

Around 300% of the company’s stock are held by insiders while 6891.7% are held by institutions.

Frequently Asked Questions About Tempest Therapeutics Inc

The stock symbol (also called stock or share ticker) of Tempest Therapeutics Inc is TPST

The IPO of Tempest Therapeutics Inc took place on 2012-11-12

Similar Industry Stocks (Biotechnology)

Last Price
Symrise Ag PK (SYIEY)

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company’s two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.


7000 Shoreline Court, South San Francisco, CA, United States, 94080